

NIS Promoted Carbochalcogenation of Styrenes: Regioselective C-3 Alkylation of Pyrazolo[1,5-*a*]pyrimidines

Abhinay S. Chillal,^{†*a*} Varsha Kumari,^{†*a*} and Umesh A. Kshirsagar^{**a*}

^aDepartment of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Indore 453552, INDIA.

Corresponding author e-mail: uakshirsagar@iiti.ac.in


Table of contents

1.	General information	3
2.	Optimization of the Reaction Conditions for carbosulfenylation reaction	4
2.	Preparation of starting materials	5-7
3.	General experimental procedure for chalcogention of pyrazolo[1,5- <i>a</i>]pyrimidines	8
4.	Experimental procedure for the scale-up synthesis of 4aa and 4ca	9
5.	Experimental procedure for the oxidation of sulfenylated derivative 4ca	9
6.	Procedure for control Experiments and EPR analysis	10-11
7.	Characterisation data of compounds (4aa-4at , 4ba-4bj , 4ca-4ce , 4d)	12-25
8.	NMR Spectra of the compounds	26-63
9.	HRMS spectra of the compounds	64-75
10.	References	76

General Information

All chemicals and reagents that were procured from commercial suppliers (TCI, Spectrochem, BLD pharma) are used without further purification. All reactions were conducted in pre-dried screw cap test tubes made of borosilicate glass. Thin layer chromatography was carried out on aluminium sheets pre-coated with Merck silica gel 60F₂₅₄ and visualised under UV light (254 nm). The organic solutions were concentrated using the Heidolph rotary evaporator under reduced pressure. Product isolation was accomplished through column chromatography on silica gel with a mesh size of 100-200 using hexanes and ethyl acetate as eluent. Nuclear magnetic resonance spectra (¹H, ¹³C, ¹⁹F) were obtained using a Fourier transform nuclear magnetic resonance spectrometer, including the Bruker Avance 500MHz model. CDCl₃ served as the solvent for spectroscopic acquisition, with chemical shifts indicated in δ values (parts per million) relative to tetramethylsilane. High-resolution mass spectrometric analyses (HRMS) were performed using an electrospray ionization time-of-flight mass spectrometer (ESI-TOF-MS), comprising Dionex Ultimate 3000 and YL9100 components. Melting points were measured with an electrothermal apparatus. All the starting materials and substrates were synthesized according to literature reports.^{1,3}


Table S1. Optimization of the Reaction Conditions for carbosulfenylation reaction^a




Sr No.	Oxidant (equiv.)	Solvent	Yield ^b (%)
1	NIS (1.0)	ACN	43
2	NIS (1.0)	DMSO	15
3	NIS (1.0)	H ₂ O	ND
4	NIS (1.0)	PEG-400	Trace
5	NIS (1.0)	-	64
6	NIS (0.6)	-	62
7	NIS (0.5)	-	48
8 ^c	NIS (0.6)	-	32
9 ^d	NIS (0.6)	-	21
10 ^e	NIS (0.6)	-	22
11 ^f	NIS (0.6)	-	33
12 ^g	NIS (0.6)	-	61
13	-	-	NR

^aReaction condition: **1a** (0.2 mmol), **2ba** (0.1 mmol), **3aa** (0.60 mmol), 60 °C, 3 h; ^bIsolated yield; ^c2.5 equiv. of styrene was used, ^d2.0 equiv. of styrene was used, ^eReaction at rt, ^fReaction at 40 °C, ^gReaction at 80 °C.


Preparation of starting materials




General procedure for the synthesis of substituted pyrazolo[1,5-*a*]pyrimidines:^{1a} In an oven-dried round bottom flask (RB), a mixture of substituted amino pyrazoles (1.0 mmol, 1.0 equiv.) and enones (1.0 mmol, 1.0 equiv.) in acetic acid (AcOH) (1.0 mL) was refluxed in an oil bath in stirring condition. The reaction was monitored by TLC analysis. After completing the reaction, the mixture was subjected to extraction using DCM and water. The organic layer was evaporated to obtain the crude pyrazolo[1,5-*a*]pyrimidine derivatives which were purified by column chromatography using 100-200 mesh silica gel and a gradient elution of ethyl acetate-hexane (1:9 to 1:4). Product conformation was done through ¹H and ¹³C NMR spectroscopic analysis.




General procedure for the synthesis of substituted pyrazolo[1,5-*a*]pyrimidines:^{1b} In an oven-dried round bottom flask (RB), substituted amino pyrazoles (1.0 mmol, 1.0 equiv.) and diketones (1.0 mmol, 1.0 equiv.) were taken. The reaction mixture was refluxed with vigorous stirring in an oil bath after adding 1.0 mL of HCl. The reaction progress was effectively monitored through TLC analysis. Upon completion of the reaction, the mixture was extracted with DCM and water. The organic layer was evaporated to obtain the crude pyrazolo[1,5-*a*]pyrimidine derivatives. Product conformation was done through ¹H and ¹³C NMR spectroscopic analysis.



Products **1a-1l** were already synthesized by us in our previous work and the same products were used as it is for this work.²




General procedure for synthesis of substituted diselenides:³ Under nitrogen atmosphere a solution containing selenium metal (Se^0) (2.0 mmol), copper oxide (CuO) nanoparticles (10.0 mol%) and halides (1.0 mmol) in dry DMSO (2.0 mL) was stirred. Potassium hydroxide (KOH) (2 equivalents) were added. The reaction mixture was heated in an oil bath, and the progress was monitored using TLC. After the reaction was completed, the mixture was cooled and then purified by column chromatography to isolate the desired diselenides. The identity of the products was confirmed through ^1H and ^{13}C NMR spectroscopic analysis.




We already synthesized products **2ab-2ai** in our previous work² and the same products were used as it is for this work.

General experimental procedure for the preparation of C3 alkylated pyrazolo[1,5-*a*]pyrimidine derivatives:




In an oven-dried reaction vessel, substituted pyrazolo[1,5-*a*]pyrimidines **1** (0.2 mmol, 1 equiv.), diorganyl dichalcogenides **2** (0.1mmol, 0.5 equiv.), substituted styrene **3a** (2.5-3.0 equiv.) and NIS (0.6 equiv.) were taken and stirred in an oil bath at 60 °C for 3 hours. Reaction progress was monitored via TLC analysis. After completion, the crude product was purified by silica gel column chromatography (100-200 mesh) to give the desired product. Product confirmation was done using ^1H and ^{13}C NMR and HRMS analysis.

Experimental procedure for the scale-up synthesis of 2,5-dimethyl-7-phenyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine (**4aa**):




2,5-Dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine **1a** (0.6 g, 2.69 mmol), diphenyl diselenide **2aa** (1.34 mmol, 0.5 equiv.), styrene **3aa** (6.72 mmol, 2.5 equiv.) and NIS (0.6 equiv.) were taken and stirred in an oil bath at 60 °C for 3 hours. Reaction progress was monitored via TLC analysis. After completion, the crude product was purified by silica gel column chromatography (100-200 mesh) to give the desired product **4aa** in 71% yield. Product confirmation was done using ¹H and ¹³C NMR and HRMS analysis.

Experimental procedure for the scale-up synthesis of 2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(phenylthio)ethyl)pyrazolo[1,5-*a*]pyrimidine (**4ca**):




2,5-Dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine **1a** (0.5 g, 2.24 mmol), diphenyl disulfide **2ba** (1.12 mmol, 0.5 equiv.), styrene **3aa** (6.72 mmol, 3.0 equiv.) and NIS (0.6 equiv.) were taken in a round bottom flask and stirred in an oil bath at 60 °C for 3 hours. Reaction progress was monitored via TLC analysis. After completion, the crude product was purified by silica gel column chromatography (100-200 mesh) to give the desired product **4ca** in 53% yield. Product confirmation was done using ¹H and ¹³C NMR and HRMS analysis.

Experimental procedure for the oxidation of sulfenylated derivative **4ca**:




2,5-dimethyl-7-phenyl-3-(1-phenyl-2-(phenylthio)ethyl)pyrazolo[1,5-*a*]pyrimidine **4ca** (40.0 mg, 1.0 equiv.), 30% H₂O₂ (6.0 equiv.), glacial acetic acid (100 μL) were taken in a 10mL round bottom flask equipped with a magnetic stir bar. The reaction was stirred at room temperature for the duration of 2 hours and the reaction progress was checked using TLC. After completion, reaction mixture was neutralised using NaHCO₃ solution and extracted with ethyl acetate (3 X 5mL). Combined organic layers were dried using Na₂SO₄, and concentrated under vacuum. Crude product was purified by silica gel column chromatography (100-200 mesh) to give desired product **4d** in 68% yield.

Procedure for control Experiments:



Scheme S5. Control experiments and detection of intermediates

Control experiments for C3 alkylation of pyrazolo[1,5-a]pyrimidines: In an oven-dried reaction vessel, substituted pyrazolo[1,5-a]pyrimidines **1aa** (0.2mmol, 1.0 equiv.), diphenyl dichalcogenides **2** (0.1mmol, 0.5 equiv.), styrene **3aa** (0.22 mmol, 2.5-3 equiv.), NIS (0.6 equiv.) and radical scavengers (DPE/ BHT, 2.0 equiv.) were taken and stirred in an oil bath at 60 °C for 3 hours. Reaction progress was monitored via TLC analysis. After completion, the crude product was purified by silica gel column chromatography to give the desired product. ¹H and ¹³C NMR did product confirmation.



Control experiment for the detection of intermediates involved in selenylation reaction:

An oven-dried screw-capped test tube was taken with a magnetic stir bar. Diphenyl diselenide (**2aa**) (0.5 equiv., 0.1 mmol), NIS (0.6 equiv.) and ACN (1.5 mL) were added to the test tube. The reaction mixture was stirred at 60 °C for 3 hours. After completion of the reaction, 100μL aliquote of the reaction mixture was taken and diluted with 1.5 mL of MeOH and immediately analyzed using LCMS analysis.

Electron Paramagnetic Resonance Spectroscopy (EPR) Study:

To check whether the reaction proceeds via a radical pathway or not, Electron paramagnetic resonance (EPR) spectra were recorded on a Bruker Biospin GmbH spectrometer at 120K temperature, and the spectra were measured at a Microwave frequency of 9.4 GHz at the X-band. The sample required for EPR analysis was prepared in MeCN solvent.




Figure S1. EPR spectrum for carboselenylation reaction mixture






Figure S2. EPR spectrum for carbosulfenylation reaction mixture


Characterization data of compounds (4aa-4as, 4ba-4bj, 4ca-4ce, 4d):



2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-a]pyrimidine(4aa): Yellow oil; 88% (85 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.91 (q, J = 3.7 Hz, 2H), 7.45 (s, 5H), 7.41 – 7.36 (m, 2H), 7.22 (d, J = 7.9 Hz, 2H), 7.11 (s, 4H), 6.52 (d, J = 3.8 Hz, 1H), 4.37 (d, J = 4.3 Hz, 1H), 4.36 – 4.29 (m, 1H), 3.68 (dd, J = 11.1, 4.7 Hz, 1H), 2.53 (s, 3H), 2.27 (s, 3H); ^{13}C { ^1H } NMR (126 MHz, CDCl_3) δ 157.2, 153.1, 147.5, 145.1, 144.8, 133.1, 131.6, 130.7, 130.6, 129.2, 128.7, 128.6, 128.5, 127.8, 126.7, 126.5, 107.9, 107.5, 43.5, 33.1, 25.0, 13.4; HRMS (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{26}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 484.1288, found 484.1283.




2-Methyl-7-phenyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-a]pyrimidine (4ab): Yellow oil; 87% (81.7 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.32 (d, J = 4.4 Hz, 1H), 7.94 (td, J = 4.6, 4.1, 2.2 Hz, 2H), 7.47 – 7.41 (m, 5H), 7.40 – 7.34 (m, 2H), 7.23 – 7.19 (m, 2H), 7.14 – 7.07 (m, 4H), 6.67 – 6.61 (m, 1H), 4.41 (dd, J = 10.4, 5.6 Hz, 1H), 4.33 – 4.27 (m, 1H), 3.69 (dd, J = 11.8, 5.6 Hz, 1H), 2.31 (s, 3H); ^{13}C { ^1H } NMR (126 MHz, CDCl_3) δ 153.4, 147.7, 145.8, 144.5, 133.0, 131.4, 130.9, 130.4, 129.3, 128.8, 128.7, 128.6, 127.7, 126.7, 126.6, 109.1, 106.5, 43.4, 33.1, 13.4; HRMS (ESI, m/z): Calculated for $\text{C}_{27}\text{H}_{24}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 470.1132, found 470.1132.




2-Methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)-7-(p-tolyl)pyrazolo[1,5-a]pyrimidine (4ac): Orange oil; 73% (72 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.41 (d, J = 4.3 Hz, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 7.2 Hz, 2H), 7.47 – 7.43 (m, 2H), 7.37 (d, J = 8.2 Hz, 2H), 7.30 (t, J = 7.6 Hz, 2H), 7.23 – 7.16 (m, 4H), 6.74 (d, J = 4.3 Hz, 1H), 4.49 (dd, J = 10.4, 5.6 Hz, 1H), 4.40 – 4.34 (m, 1H), 3.77 (dd, J = 11.9, 5.6 Hz, 1H), 2.46 (s, 3H), 2.40 (s, 3H). ^{13}C { ^1H } NMR (126 MHz, CDCl_3) δ 153.3, 147.8, 147.7, 146.0, 144.6, 141.3, 133.1,


130.5, 129.4, 129.2, 128.8, 128.6, 128.5, 127.8, 126.7, 126.6, 109.0, 106.2, 43.5, 33.1, 21.6, 13.4; **HRMS** (ESI, m/z): Calculated for $C_{28}H_{26}N_3Se$ $[M+H]^+$: 484.1288, found 484.1290.




7-(4-Methoxyphenyl)-2-methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4ad): Brown oil; 82% (82 mg); 1H NMR (500 MHz, $CDCl_3$) δ 8.39 (d, J = 4.3 Hz, 1H), 8.06 (d, J = 8.9 Hz, 2H), 7.50 (d, J = 9.2 Hz, 2H), 7.44 (dd, J = 6.6, 3.1 Hz, 2H), 7.29 (t, J = 7.6 Hz, 2H), 7.23 – 7.14 (m, 4H), 7.06 (d, J = 9.0 Hz, 2H), 6.72 (d, J = 4.3 Hz, 1H), 4.48 (dd, J = 10.5, 5.6 Hz, 1H), 4.41 – 4.30 (m, 1H), 3.89 (s, 3H), 3.76 (dd, J = 11.9, 5.6 Hz, 1H), 2.39 (s, 3H). ^{13}C $\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 161.7, 153.22, 147.8, 147.7, 145.6, 144.6, 133.1, 131.0, 130.5, 128.8, 128.6, 127.8, 126.7, 126.6, 123.6, 114.1, 108.9, 105.8, 55.5, 43.4, 33.1, 13.4; **HRMS** (ESI, m/z): Calculated for $C_{28}H_{26}N_3OSe$ $[M+H]^+$: 500.1237, found 500.1240.




7-(3-Methoxyphenyl)-2-methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4ae): Yellow oil; 87% (86.8 mg); 1H NMR (500 MHz, $CDCl_3$) δ 8.38 (d, J = 4.3 Hz, 1H), 7.63 – 7.60 (m, 1H), 7.55 – 7.47 (m, 3H), 7.45 – 7.40 (m, 3H), 7.28 (d, J = 7.5 Hz, 2H), 7.20 – 7.14 (m, 4H), 7.06 (dd, J = 8.2, 3.0 Hz, 1H), 6.71 (d, J = 4.3 Hz, 1H), 4.48 (dd, J = 10.5, 5.6 Hz, 1H), 4.40 – 4.32 (m, 1H), 3.84 (s, 3H), 3.75 (dd, J = 11.9, 5.6 Hz, 1H), 2.38 (s, 3H); ^{13}C $\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 159.5, 153.3, 147.7, 147.6, 145.6, 144.5, 133.0, 132.5, 130.3, 129.7, 128.7, 128.5, 127.7, 126.7, 126.6, 121.7, 116.6, 114.8, 109.1, 106.5, 55.4, 43.4, 33.0, 13.4; **HRMS** (ESI, m/z): Calculated for $C_{28}H_{26}N_3OSe$ $[M+H]^+$: 500.1237, found 500.1238.



4-(2-Methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile(4af): Orange oil; 78% (77.1 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.42 (d, J = 4.3 Hz, 1H), 8.11 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.38 (dd, J = 6.5, 3.1 Hz, 2H), 7.26 – 7.21 (m, 2H), 7.20 – 7.08 (m, 4H), 6.72 (d, J = 4.3 Hz, 1H), 4.42 (dd, J = 10.6, 5.4 Hz, 1H), 4.36 – 4.25 (m, 1H), 3.69 (dd, J = 11.8, 5.4 Hz, 1H), 2.33 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 153.9, 147.6, 144.3, 143.6, 135.7, 133.1, 132.5, 130.2, 130.0, 128.9, 128.7, 127.7, 126.9, 126.8, 118.3, 114.4, 109.8, 106.9, 43.4, 33.1, 13.3; **HRMS** (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{23}\text{N}_4\text{Se}$ $[\text{M}+\text{H}]^+$: 495.1084, found 495.1083.




7-(4-Chlorophenyl)-2-methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4ag): Yellow jelly; 91% (91.5 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.33 (d, J = 4.4 Hz, 1H), 7.90 (d, J = 8.5 Hz, 2H), 7.43 (t, J = 7.6 Hz, 4H), 7.39 – 7.31 (m, 2H), 7.24 – 7.18 (m, 2H), 7.17 – 7.02 (m, 4H), 6.62 (d, J = 4.6 Hz, 1H), 4.45 – 4.36 (m, 1H), 4.34 – 4.23 (m, 1H), 3.74 – 3.58 (m, 1H), 2.31 (d, J = 2.6 Hz, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 153.5, 147.7, 147.6, 144.6, 144.5, 137.0, 133.0, 130.6, 130.4, 129.7, 129.0, 128.8, 128.6, 127.7, 126.7, 126.6, 109.3, 106.3, 43.4, 33.0, 13.3; **HRMS** (ESI, m/z): Calculated for $\text{C}_{27}\text{H}_{23}\text{ClN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 504.0739, found 504.0739.




7-(4-Fluorophenyl)-2-methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4ah): Yellow gummy mass; 91% (88.6 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.33 (d, J = 4.3 Hz, 1H), 7.97 (dd, J = 8.7, 5.5 Hz, 2H), 7.42 (d, J = 7.8 Hz, 2H), 7.36 (dd, J = 6.6, 3.0 Hz, 2H), 7.21 (t, J = 7.6 Hz, 2H), 7.18 – 7.08 (m, 6H), 6.62 (d, J = 4.4 Hz, 1H), 4.41


(dd, $J = 10.5, 5.5$ Hz, 1H), 4.29 (t, $J = 11.1$ Hz, 1H), 3.68 (dd, $J = 11.8, 5.6$ Hz, 1H), 2.31 (s, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 165.1, 163.1, 153.5, 147.7, 147.6, 144.7, 144.5, 133.0, 131.5, 131.4, 130.4, 128.8, 128.6, 127.7, 127.4, 127.3, 126.7, 126.6, 115.9, 115.8, 109.2, 106.3, 43.4, 33.0, 13.3; **HRMS** (ESI, m/z): Calculated for $\text{C}_{27}\text{H}_{23}\text{FN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 488.1037, found 488.1037.




7-(4-Bromophenyl)-2-methyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4ai): Yellow oil; 87% (95.2 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.38 (d, $J = 4.4$ Hz, 1H), 7.91 – 7.84 (m, 2H), 7.68 – 7.61 (m, 2H), 7.46 – 7.41 (m, 2H), 7.41 – 7.36 (m, 2H), 7.25 (s, 1H), 7.24 – 7.21 (m, 1H), 7.18 – 7.10 (m, 4H), 6.69 (d, $J = 4.3$ Hz, 1H), 4.43 (dd, $J = 10.5, 5.6$ Hz, 1H), 4.36 – 4.26 (m, 1H), 3.70 (dd, $J = 11.9, 5.5$ Hz, 1H), 2.33 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 153.6, 147.7, 147.6, 144.8, 144.5, 133.1, 132.0, 130.9, 130.4, 130.2, 128.8, 128.6, 127.8, 126.8, 126.7, 125.5, 109.4, 106.3, 43.5, 33.0, 13.4; **HRMS** (ESI, m/z): Calculated for $\text{C}_{27}\text{H}_{23}\text{BrN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 548.0234, found 548.0231.




2-Methyl-7-(naphthalen-2-yl)-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4aj): Orange oil; 71% (73.7 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.49 (s, 1H), 8.37 (d, $J = 4.1$ Hz, 1H), 7.98 (d, $J = 8.5$ Hz, 1H), 7.89 (t, $J = 9.5$ Hz, 2H), 7.83 (d, $J = 9.2$ Hz, 1H), 7.48 (dd, $J = 15.2, 7.7$ Hz, 4H), 7.43 – 7.37 (m, 2H), 7.24 (d, $J = 7.8$ Hz, 2H), 7.18 – 7.09 (m, 4H), 6.75 (d, $J = 4.3$ Hz, 1H), 4.46 (dd, $J = 10.5, 5.6$ Hz, 1H), 4.34 (t, $J = 11.1$ Hz, 1H), 3.73 (dd, $J = 11.9, 5.6$ Hz, 1H), 2.35 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 153.4, 147.7, 145.9, 144.5, 134.4, 133.0, 132.9, 130.4, 129.8, 129.0, 128.8, 128.7, 128.6, 128.2, 127.8, 127.7, 127.6, 126.7, 126.6, 126.5, 125.7, 109.2, 106.8, 43.4, 33.0, 13.4; **HRMS** (ESI, m/z): Calculated for $\text{C}_{31}\text{H}_{26}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 520.1289, found 520.1288.



7-phenyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4ak): Yellow oil; 83% (75.5 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.38 (d, $J = 4.3$ Hz, 1H), 8.02 (s, 1H), 7.92 (dd, $J = 6.7, 3.1$ Hz, 2H), 7.50 – 7.45 (m, 3H), 7.40 (dd, $J = 7.2, 2.4$ Hz, 4H), 7.24 (d, $J = 7.9$ Hz, 2H), 7.14 (ddd, $J = 16.2, 5.9, 1.9$ Hz, 4H), 6.73 (d, $J = 4.3$ Hz, 1H), 4.73 – 4.62 (m, 1H), 3.97 (dd, $J = 12.0, 9.1$ Hz, 1H), 3.61 (dd, $J = 12.1, 6.9$ Hz, 1H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 148.1, 146.8, 146.5, 144.0, 143.5, 132.8, 131.0, 130.9, 130.6, 129.2, 128.9, 128.7, 128.6, 127.7, 126.7, 112.5, 107.3, 42.6, 34.0; HRMS (ESI, m/z): Calculated for $\text{C}_{26}\text{H}_{22}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 456.0975, found 456.0989.




2,5,7-trimethyl-3-(1-phenyl-2-(phenylselanyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4al): Brown oil; 79% (66.5 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.45 – 7.39 (m, 4H), 7.26 – 7.22 (m, 2H), 7.17 (q, $J = 3.6$ Hz, 4H), 6.42 (s, 1H), 4.42 – 4.31 (m, 2H), 3.70 (dd, $J = 11.3, 5.2$ Hz, 1H), 2.64 (s, 3H), 2.54 (s, 3H), 2.33 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.3, 152.8, 146.5, 144.7, 144.4, 133.0, 130.6, 128.8, 128.6, 127.8, 126.8, 126.6, 108.0, 107.7, 43.2, 33.4, 24.9, 17.2, 13.2; HRMS (ESI, m/z): Calculated for $\text{C}_{23}\text{H}_{24}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 422.1131, found 422.1135.




2,5-Dimethyl-7-phenyl-3-(2-(phenylselanyl)-1-(p-tolyl)ethyl)pyrazolo[1,5-*a*]pyrimidine(4am): Yellow jelly; 85% (84.5 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.95 – 7.89 (m, 2H), 7.48 – 7.44 (m, 3H), 7.41 – 7.36 (m, 2H), 7.34 (d, $J = 8.1$ Hz, 2H), 7.14 – 7.08 (m, 3H), 7.04 (d, $J = 8.1$ Hz, 2H), 6.52 (s, 1H), 4.37 (dd, $J = 10.2, 5.3$ Hz, 1H), 4.34 – 4.27 (m, 1H), 3.69 (dd, $J = 11.4, 5.5$ Hz, 1H), 2.54 (s, 3H), 2.28 (s, 3H), 2.24 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.2, 153.1, 147.4, 145.1, 141.9, 136.0, 133.0, 131.6, 130.7,


129.3, 129.2, 129.1, 128.7, 128.6, 127.7, 126.6, 108.1, 107.4, 43.0, 33.2, 25.0, 21.1, 13.4; **HRMS** (ESI, m/z): Calculated for $C_{29}H_{28}N_3Se$ $[M+H]^+$: 498.1445, found 498.1452.



3-(1-(4-(tert-butyl)phenyl)-2-(phenylselanyl)ethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4an): Orange oil; 82% (88.4 mg); 1H NMR (500 MHz, $CDCl_3$) δ 8.00 (dd, J = 6.6, 3.1 Hz, 2H), 7.57 – 7.52 (m, 3H), 7.49 – 7.42 (m, 4H), 7.33 (d, J = 8.4 Hz, 2H), 7.22 – 7.15 (m, 3H), 6.61 (s, 1H), 4.44 (d, J = 7.9 Hz, 2H), 3.77 – 3.67 (m, 1H), 2.63 (s, 3H), 2.38 (s, 3H), 1.32 (s, 9H); ^{13}C $\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 157.1, 153.2, 149.2, 147.4, 145.1, 141.9, 133.1, 131.6, 130.7, 130.6, 129.3, 128.7, 128.6, 127.5, 126.6, 125.4, 108.1, 107.4, 43.1, 34.5, 33.3, 31.5, 25.0, 13.6; **HRMS** (ESI, m/z): Calculated for $C_{32}H_{34}N_3Se$ $[M+H]^+$: 540.1915, found 540.1915.




4-(1-(2,5-Dimethyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)-2-(phenylselanyl)ethyl)phenyl acetate(4ao): Yellow jelly; 78% (84.4 mg); 1H NMR (500 MHz, $CDCl_3$) δ 7.89 – 7.83 (m, 2H), 7.42 – 7.37 (m, 5H), 7.31 (dd, J = 6.6, 3.1 Hz, 2H), 7.07 – 7.02 (m, 3H), 6.88 (d, J = 8.7 Hz, 2H), 6.48 (s, 1H), 4.33 – 4.23 (m, 2H), 3.59 (dd, J = 10.9, 4.5 Hz, 1H), 2.47 (s, 3H), 2.22 (s, 3H), 2.14 (s, 3H); ^{13}C $\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 168.5, 156.2, 152.0, 148.1, 146.3, 144.1, 141.3, 132.0, 130.4, 129.6, 129.3, 128.1, 127.7, 127.6, 127.5, 125.6, 120.3, 106.5, 106.4, 41.8, 32.1, 23.9, 20.1, 12.2; **HRMS** (ESI, m/z): Calculated for $C_{30}H_{27}N_3O_2SeNa$ $[M+Na]^+$: 564.1163, found 564.1162.




3-(1-(4-Chlorophenyl)-2-(phenylselanyl)ethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4ap): Yellow oil; 71% (73.4 mg); 1H NMR (500 MHz, $CDCl_3$) δ 7.97 (dd, J =


6.7, 3.1 Hz, 2H), 7.54 – 7.51 (m, 3H), 7.43 – 7.39 (m, 4H), 7.23 (d, $J = 8.5$ Hz, 2H), 7.19 – 7.15 (m, 3H), 6.61 (s, 1H), 4.42 – 4.36 (m, 1H), 4.31 – 4.25 (m, 1H), 3.71 (dd, $J = 11.9, 6.0$ Hz, 1H), 2.61 (s, 3H), 2.31 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.5, 153.1, 147.2, 145.5, 143.2, 133.2, 132.3, 131.5, 130.9, 130.4, 129.3, 129.2, 128.8, 128.7, 128.6, 126.9, 107.6, 107.5, 42.9, 33.0, 25.0, 13.4; **HRMS** (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{ClN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 518.0896, found 518.0904.




3-(1-(4-Fluorophenyl)-2-(phenylselanyl)ethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine(4aq): Yellow oil; 89% (89.2 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.03 – 7.95 (m, 2H), 7.57 – 7.51 (m, 3H), 7.50 – 7.41 (m, 4H), 7.23 – 7.14 (m, 3H), 7.02 – 6.93 (m, 2H), 6.62 (s, 1H), 4.43 (dd, $J = 9.9, 6.0$ Hz, 1H), 4.31 (dd, $J = 12.0, 10.0$ Hz, 1H), 3.73 (dd, $J = 11.9, 6.0$ Hz, 1H), 2.62 (s, 3H), 2.34 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 162.3, 160.4, 157.2, 152.8, 147.1, 145.1, 140.3, 140.3, 132.9, 131.3, 130.5, 130.2, 129.1, 129.0, 128.9, 128.5, 128.4, 126.5, 115.1, 114.9, 107.6, 107.3, 42.5, 33.0, 24.7, 13.1; **HRMS** (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{FN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 502.1194, found 502.1193.




3-(1-(4-Bromophenyl)-2-(phenylselanyl)ethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine(4ar): Brown oil; 68% (76.3 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.98 (dd, $J = 6.6, 3.1$ Hz, 2H), 7.66 – 7.46 (m, 4H), 7.42 (dd, $J = 6.6, 3.1$ Hz, 2H), 7.38 (d, $J = 1.7$ Hz, 3H), 7.20 – 7.15 (m, 3H), 6.62 (s, 1H), 4.39 (dd, $J = 9.9, 6.0$ Hz, 1H), 4.31 – 4.23 (m, 1H), 3.72 (dd, $J = 12.0, 6.0$ Hz, 1H), 2.61 (s, 3H), 2.32 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.5, 153.1, 147.3, 145.4, 143.7, 133.2, 131.6, 131.5, 130.8, 130.3, 129.7, 129.3, 128.8, 128.7, 126.8, 120.4, 107.6, 107.5, 42.9, 32.9, 25.0, 13.4; **HRMS** (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{BrN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 562.0391, found 562.0380.



2,5-Dimethyl-3-(1-(naphthalen-2-yl)-2-(phenylselanyl)ethyl)-7-phenylpyrazolo[1,5-a]pyrimidine(4as): Brown jelly; 81% (86.4 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.00 (dd, J = 6.8, 3.0 Hz, 2H), 7.86 (s, 1H), 7.82 – 7.74 (m, 3H), 7.70 (d, J = 8.4 Hz, 1H), 7.57 – 7.50 (m, 3H), 7.50 – 7.39 (m, 4H), 7.23 – 7.14 (m, 3H), 6.63 (s, 1H), 4.70 – 4.55 (m, 1H), 4.44 (t, J = 11.1 Hz, 1H), 3.86 (dd, J = 12.0, 5.9 Hz, 1H), 2.65 (s, 3H), 2.36 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.4, 153.4, 147.4, 145.4, 142.1, 133.6, 133.1, 132.4, 131.6, 130.8, 130.7, 129.3, 128.8, 128.7, 128.3, 127.9, 127.7, 126.8, 126.7, 126.0, 125.9, 125.5, 107.9, 107.6, 43.5, 33.0, 25.0, 13.5; HRMS (ESI, m/z): Calculated for $\text{C}_{32}\text{H}_{28}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 534.1445, found 534.1445.




2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(p-tolylselanyl)ethyl)pyrazolo[1,5-a]pyrimidine(4ba): Yellow jelly; 80% (79.5 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.92 (dd, J = 6.8, 3.0 Hz, 2H), 7.50 – 7.39 (m, 5H), 7.28 (s, 2H), 7.21 (t, J = 7.6 Hz, 2H), 7.12 (t, J = 7.3 Hz, 1H), 6.92 (d, J = 8.1 Hz, 2H), 6.53 (s, 1H), 4.38 (dd, J = 10.5, 5.4 Hz, 1H), 4.29 (t, J = 11.1 Hz, 1H), 3.62 (dd, J = 11.7, 5.5 Hz, 1H), 2.54 (s, 3H), 2.28 (s, 3H), 2.22 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.2, 153.2, 147.4, 145.2, 144.9, 136.6, 133.6, 131.6, 130.7, 129.5, 129.3, 128.6, 128.5, 127.8, 126.7, 126.5, 108.0, 107.4, 43.5, 33.4, 25.0, 21.2, 13.4; HRMS (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 498.1445, found 498.1444.




2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(o-tolylselanyl)ethyl)pyrazolo[1,5-a]pyrimidine(4bb): Yellow jelly; 86% (85.5 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.95 (dd, J = 6.8, 2.8 Hz, 2H), 7.54 – 7.45 (m, 5H), 7.40 (d, J = 7.8 Hz, 1H), 7.28 – 7.23 (m, 2H), 7.17 (t, J = 7.4 Hz, 1H), 7.06 (dd, J = 13.4, 7.5 Hz, 2H), 7.03 – 6.96 (m, 1H), 6.58 (s, 1H), 4.43 (dd, J = 10.4, 5.5 Hz, 1H), 4.35 (t, J = 10.9 Hz, 1H), 3.71 – 3.60 (m, 1H), 2.58 (s, 3H), 2.31 (d, J =


2.0 Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.3, 153.2, 147.4, 145.2, 144.9, 139.9, 132.6, 131.6, 131.6, 130.8, 129.7, 129.3, 128.7, 128.6, 127.9, 126.7, 126.6, 126.2, 108.1, 107.5, 43.3, 32.0, 24.99, 22.58, 13.44; **HRMS** (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 498.1445, found 498.1441.




3-(2-((4-Methoxyphenyl)selanyl)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4bc): Yellow oil; 87% (89.3 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.99 (dd, J = 6.6, 3.0 Hz, 2H), 7.58 – 7.51 (m, 3H), 7.48 (d, J = 7.5 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.30 – 7.25 (m, 2H), 7.18 (t, J = 7.4 Hz, 1H), 6.70 (d, J = 8.7 Hz, 2H), 6.59 (s, 1H), 4.42 (dd, J = 10.7, 5.0 Hz, 1H), 4.34 (t, J = 11.1 Hz, 1H), 3.75 (s, 3H), 3.61 (dd, J = 11.7, 5.1 Hz, 1H), 2.60 (s, 3H), 2.37 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 159.1, 157.2, 153.2, 147.9, 145.1, 145.0, 135.8, 131.6, 130.7, 129.3, 128.6, 128.5, 127.8, 126.5, 120.3, 114.3, 107.9, 107.4, 55.3, 43.7, 33.9, 25.0, 13.5; **HRMS** (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{OSe}$ $[\text{M}+\text{H}]^+$: 514.1394, found 514.1395.




2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-((4-(trifluoromethyl)phenyl)selanyl)ethyl)pyrazolo[1,5-a]pyrimidine(4bd): Yellow gummy mass; 88% (97.0 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.98 (dt, J = 5.2, 3.0 Hz, 2H), 7.56 – 7.50 (m, 5H), 7.48 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.30 (t, J = 7.6 Hz, 2H), 7.22 (d, J = 7.3 Hz, 1H), 6.60 (s, 1H), 4.58 – 4.35 (m, 2H), 3.80 (dd, J = 11.3, 5.0 Hz, 1H), 2.59 (s, 3H), 2.36 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.4, 153.2, 147.4, 145.3, 144.5, 136.4, 132.4, 131.4, 130.9, 129.3, 128.7, 128.6, 128.4, 127.9, 126.8, 125.3 (q, J = 3.9 Hz), 107.7, 107.5, 43.8, 33.1, 25.0, 13.5; **HRMS** (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{25}\text{F}_3\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 552.1162, found 552.1165.



3-(2-((4-Chlorophenyl)selanyl)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4be): Brown oil; 84% (86.9 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.02 (dd, J = 6.5, 3.3 Hz, 2H), 7.61 – 7.47 (m, 5H), 7.36 – 7.27 (m, 4H), 7.25 – 7.18 (m, 1H), 7.10 (dd, J = 8.5, 2.1 Hz, 2H), 6.61 (s, 1H), 4.44 (m, 2H), 3.70 (m, 1H), 2.60 (s, 3H), 2.39 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.3, 153.1, 147.4, 145.1, 144.7, 134.8, 132.9, 131.5, 130.8, 129.3, 128.6, 128.5, 127.8, 126.6, 107.6, 107.4, 44.0, 33.9, 24.9, 13.4; HRMS (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{ClN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 518.0896, found 518.0897.




3-(2-((3-Chlorophenyl)selanyl)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4bf): Yellow oil; 84% (86.9 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.97 (dd, J = 6.7, 3.1 Hz, 2H), 7.56 – 7.46 (m, 5H), 7.40 (s, 1H), 7.30 – 7.22 (m, 3H), 7.19 (t, J = 7.9 Hz, 1H), 7.09 (d, J = 8.1 Hz, 1H), 7.03 (t, J = 7.9 Hz, 1H), 6.60 (s, 1H), 4.56 – 4.29 (m, 2H), 3.72 (dd, J = 11.1, 4.7 Hz, 1H), 2.61 (s, 3H), 2.35 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.4, 153.1, 147.4, 145.2, 144.6, 134.2, 132.5, 132.3, 131.5, 130.9, 130.7, 129.6, 129.3, 128.6, 128.5, 127.8, 126.7, 126.7, 107.6, 107.5, 43.8, 33.3, 25.0, 13.4; HRMS (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{ClN}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 518.0896, found 518.0901.




3-(2-((4-bromophenyl)selanyl)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4bg): Yellow oil; 82% (92.0 mg); ^1H NMR (500 MHz, CDCl_3) δ 8.04 – 7.97 (m, 2H), 7.57 – 7.48 (m, 5H), 7.29 (t, J = 7.6 Hz, 2H), 7.22 (s, 5H), 6.61 (s, 1H), 4.45 (dd, J = 10.7, 4.9 Hz, 1H), 4.38 (t, J = 11.2 Hz, 1H), 3.67 (dd, J = 11.6, 4.9 Hz, 1H), 2.59 (s, 3H), 2.38 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.3, 153.2, 147.3, 145.2, 144.7, 135.1, 131.6,


131.5, 130.8, 129.5, 129.3, 128.7, 128.6, 127.8, 126.7, 121.0, 107.7, 107.4, 44.1, 33.6, 25.0, 13.5; **HRMS** (ESI, m/z): Calculated for $C_{28}H_{25}BrN_3Se$ $[M+H]^+$: 562.0391, found 562.0397.



3-(2-((3-Bromophenyl)selanyl)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine(4bh): Yellow oil; 82% (92.0 mg); 1H NMR (500 MHz, $CDCl_3$) δ 7.97 (dd, J = 6.8, 3.0 Hz, 2H), 7.64 – 7.42 (m, 6H), 7.30 – 7.25 (m, 4H), 7.19 (t, J = 7.3 Hz, 1H), 6.98 (t, J = 7.9 Hz, 1H), 6.61 (s, 1H), 4.56 – 4.25 (m, 2H), 3.71 (dd, J = 11.4, 5.0 Hz, 1H), 2.63 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 157.5, 153.2, 147.4, 145.3, 144.6, 135.4, 132.7, 131.6, 131.5, 130.8, 130.0, 129.7, 129.4, 128.7, 128.6, 127.9, 126.7, 122.5, 107.7, 107.6, 43.8, 33.4, 25.1, 13.5; **HRMS** (ESI, m/z): Calculated for $C_{28}H_{25}BrN_3Se$ $[M+H]^+$: 562.0391, found 562.0389.




3-(2-((4-Bromophenyl)selanyl)-1-phenylethyl)-2-methyl-7-phenylpyrazolo[1,5-a]pyrimidine(4bi): Yellow oil; 78% (85.3 mg); 1H NMR (500 MHz, $CDCl_3$) δ 8.37 (d, J = 4.3 Hz, 1H), 8.07 – 8.01 (m, 2H), 7.57 – 7.52 (m, 3H), 7.48 (d, J = 9.9 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.21 (d, J = 2.7 Hz, 5H), 6.75 (d, J = 4.3 Hz, 1H), 4.46 (q, J = 6.5, 5.3 Hz, 1H), 4.41 – 4.28 (m, 1H), 3.68 (ddd, J = 14.6, 5.2, 2.5 Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 153.5, 147.8, 146.0, 144.4, 134.9, 131.7, 131.3, 131.1, 129.4, 129.3, 128.8, 128.7, 127.8, 126.8, 121.1, 108.9, 106.5, 44.0, 33.5, 13.5; **HRMS** (ESI, m/z): Calculated for $C_{27}H_{23}BrN_3Se$ $[M+H]^+$: 5548.0234, found 548.0232.




3-(2-(benzylselanyl)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-

a]pyrimidine(4bj): Yellow oil; 67% (66.6 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.96 (dd, J = 6.6, 3.1 Hz, 2H), 7.53 – 7.47 (m, 3H), 7.39 (d, J = 8.5 Hz, 2H), 7.29 – 7.25 (m, 4H), 7.25 – 7.22 (m, 2H), 7.21 – 7.12 (m, 2H), 6.61 (s, 1H), 4.26 (dd, J = 9.7, 6.6 Hz, 1H), 3.86 (dd, J = 12.1, 9.6 Hz, 1H), 3.71 (s, 2H), 3.42 (dd, J = 12.1, 6.7 Hz, 1H), 2.60 (s, 3H), 2.27 (s, 3H); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.4, 153.2, 147.5, 145.4, 144.9, 140.1, 131.6, 130.8, 129.3, 129.0, 128.7, 128.6, 128.5, 127.9, 126.7, 126.5, 108.5, 107.5, 43.3, 29.5, 27.8, 25.0, 13.6; HRMS (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{Se}$ $[\text{M}+\text{H}]^+$: 498.1445, found 498.1448.




2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(phenylthio)ethyl)pyrazolo[1,5-a]pyrimidine(4ca):

Brown oil; 62% (54.0 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.98 – 7.93 (m, 2H), 7.54 – 7.49 (m, 3H), 7.47 (d, J = 7.2 Hz, 2H), 7.29 (t, J = 7.2 Hz, 3H), 7.24 (d, J = 4.6 Hz, 1H), 7.22 – 7.15 (m, 3H), 7.12 (t, J = 7.3 Hz, 1H), 6.60 (s, 1H), 4.34 (d, J = 9.3 Hz, 2H), 3.81 – 3.72 (m, 1H), 2.59 (s, 3H), 2.28 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.4, 153.3, 147.6, 145.3, 144.2, 136.5, 131.7, 130.7, 130.1, 129.3, 128.8, 128.7, 128.6, 128.0, 126.7, 126.1, 107.6, 107.5, 42.4, 39.0, 25.1, 13.4; HRMS (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{26}\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$: 436.1842, found 436.1841.




2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(p-tolylthio)ethyl)pyrazolo[1,5-a]pyrimidine(4cb):


Yellow jelly; 56% (50.2 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.97 (dd, J = 6.0, 3.9 Hz, 2H), 7.57 – 7.41 (m, 5H), 7.26 (d, J = 15.1 Hz, 2H), 7.22 – 7.13 (m, 3H), 7.01 (d, J = 7.9 Hz, 2H), 6.60 (s, 1H), 4.32 (d, J = 12.7 Hz, 2H), 3.70 (dd, J = 11.2, 4.2 Hz, 1H), 2.60 (s, 3H), 2.29 (d, J = 10.8 Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.3, 153.4, 147.4, 145.3, 144.3, 136.2, 132.7, 131.6, 130.9, 130.8, 129.5, 129.3, 128.7, 128.6, 128.0, 126.6, 107.6, 107.5, 42.5, 39.4, 25.0, 21.2, 13.5; HRMS (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$: 450.1998, found 450.1993.



3-(2-((4-Methoxyphenyl)thio)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine(4cc): Yellow oil; 61% (57.3 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.99 (dd, J = 6.4, 2.9 Hz, 2H), 7.54 (d, J = 4.7 Hz, 3H), 7.46 (d, J = 7.3 Hz, 2H), 7.29 – 7.24 (m, 4H), 7.18 (t, J = 7.3 Hz, 1H), 6.73 (d, J = 8.7 Hz, 2H), 6.64 (s, 1H), 4.52 (d, J = 11.1 Hz, 1H), 4.25 (t, J = 11.7 Hz, 1H), 3.75 (s, 3H), 3.65 (d, J = 18.5 Hz, 1H), 2.69 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 158.9, 157.6, 154.0, 146.3, 144.0, 133.7, 131.2, 129.5, 128.8, 128.6, 128.0, 126.6, 114.3, 107.7, 107.5, 55.4, 42.4, 40.4, 24.6, 13.7; **HRMS** (ESI, m/z): Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{OS}$ $[\text{M}+\text{H}]^+$: 466.1948, found 466.1946.




3-(2-((4-Chlorophenyl)thio)-1-phenylethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine(4cd): Yellow oil; 60% (55.8 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.98 (dd, J = 6.6, 2.6 Hz, 2H), 7.56 – 7.47 (m, 5H), 7.28 (t, J = 7.4 Hz, 2H), 7.22 – 7.17 (m, 3H), 7.13 (d, J = 8.4 Hz, 2H), 6.62 (s, 1H), 4.43 – 4.27 (m, 2H), 3.72 (dd, J = 12.5, 5.2 Hz, 1H), 2.62 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.5, 153.5, 147.1, 145.6, 143.9, 135.1, 132.1, 131.7, 131.4, 131.0, 129.4, 128.8, 128.7, 128.6, 128.0, 126.8, 107.6, 107.3, 42.8, 39.3, 25.0, 13.5; **HRMS** (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$: 470.1452, found 470.1452.



3-(1-(4-(tert-butyl)phenyl)-2-(phenylthio)ethyl)-2,5-dimethyl-7-phenylpyrazolo[1,5-*a*]pyrimidine(4ce): Brown oil; 57% (53.1 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.98 (dd, J = 6.8, 3.0 Hz, 2H), 7.55 – 7.50 (m, 3H), 7.44 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.2 Hz, 4H), 7.23 – 7.19 (m, 2H), 7.15 – 7.10 (m, 1H), 6.62 (s, 1H), 4.47 – 4.28 (m, 2H), 3.75 (dd, J = 12.4, 5.2



Hz, 1H), 2.64 (s, 3H), 2.33 (s, 3H), 1.29 (s, 9H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.4, 153.6, 149.3, 147.0, 145.6, 141.1, 136.7, 131.5, 130.9, 130.0, 129.4, 128.7, 128.6, 127.6, 125.9, 125.5, 107.7, 107.5, 41.9, 38.9, 34.5, 31.5, 24.8, 13.5; **HRMS** (ESI, m/z): Calculated for $\text{C}_{32}\text{H}_{34}\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$: 492.2468, found 492.2464.





2,5-Dimethyl-7-phenyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)pyrazolo[1,5-a]pyrimidine(4d): Off white solid; m.p. 184-186 °C; 68% (29.2 mg); ^1H NMR (500 MHz, CDCl_3) δ 7.91 – 7.81 (m, 2H), 7.56 – 7.49 (m, 3H), 7.49 – 7.44 (m, 2H), 7.43 – 7.36 (m, 2H), 7.26 (d, J = 7.3 Hz, 2H), 7.17 (dd, J = 19.0, 7.4 Hz, 2H), 7.06 (t, J = 7.8 Hz, 2H), 6.45 (s, 1H), 5.31 (dd, J = 14.6, 11.4 Hz, 1H), 4.73 (dd, J = 11.5, 3.3 Hz, 1H), 3.68 (dd, J = 14.6, 3.2 Hz, 1H), 2.51 (s, 3H), 2.47 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.3, 152.9, 146.9, 145.0, 142.8, 139.5, 132.1, 131.2, 131.0, 129.1, 128.9, 128.8, 127.7, 127.5, 127.3, 127.1, 107.3, 105.3, 59.2, 38.0, 24.9, 13.1; **HRMS** (ESI, m/z): Calculated for $\text{C}_{28}\text{H}_{25}\text{N}_3\text{O}_2\text{SNa}$ $[\text{M}+\text{Na}]^+$: 490.1565, found 490.1564.



NMR spectra of compounds

4aa (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)







4ab (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)









4ad (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)















4ah (^{19}F NMR 471 MHz, CDCl_3)













4al (^1H 500MHz/ $^{13}\text{C}\{^1\text{H}\}$ 126MHz- CDCl_3)





7.43, 7.43, 7.42, 7.41, 7.41, 7.25, 7.23, 7.18, 7.17, 7.16, 7.15, 6.42, 4.41, 4.40, 4.39, 4.38, 4.36, 4.33, 4.31, 3.72, 3.71, 3.70, 3.69, 2.64, 2.54, 2.33





157.32, 152.79, 146.48, 144.69, 144.37, 132.97, 130.55, 128.81, 128.55, 127.82, 126.77, 126.58, 108.00, 107.66, 43.23, 33.40, 24.88, 17.21, 13.23








4an (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)








4ap (^1H 500MHz/ $^{13}\text{C}\{^1\text{H}\}$ 126MHz- CDCl_3)









4ah (^{19}F NMR 471 MHz, CDCl_3)















4bd (^{19}F NMR 471 MHz, CDCl_3)


— -62.43












4bg (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)












4bj (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)






4ca (^1H 500MHz/ $^{13}\text{C}\{^1\text{H}\}$ 126MHz- CDCl_3)






4cb (^1H 500MHz/ ^{13}C { ^1H } 126MHz- CDCl_3)


























HRMS spectra of the compounds (4aa-4at, 4ba-4bj, 4ca-4ce, 4d)













































References

- 1) a) M. A. P. Martins, E. Scapin, C. P. Frizzo, F. A. Rosa, H. G. Bonacorso, N. Zanatta, *J Braz Chem Soc*, **2009**, 20, 205-213; b) L. Yin and J. Liebscher, *Synthesis*, **2004**, 2004, 2329-2334.
- 2) Chillal, A. S.; Bhawale, R. T.; Kshirsagar, U. A., *ChemistrySelect* **2024**, 9, e202304815.
- 3) D. Singh, A. M. Deobald, L. R. S. Camargo, G. Tabarelli, O. E. D. Rodrigues, A. L. Braga, *Org. Lett.* **2010**, 12, 3288-3291.